The lead molecule under development by NDR for treating neuroinflammation is the retro-inverso thymopentin, TVALA®. The application for the novel drug is intended for use in ALS but it may be beneficial in renal dialysis patients as well as for Covid19 infections. TVALA® is the first molecule being developed by NDR. The potential ALS treatment was designed in a program to develop non-hydrolyzing analogs of anti-inflammatory peptides. TVALA® is scheduled for FDA review and into clinical trial less than 24 months after its conception in the laboratory. If successful, NDR may lead the way in shortening the pipeline of treatments to ALS patients by keeping the drug in the not-for-profit space.
top of page
Recent Posts
See AllNDR contributed to the work that was published by Dr. Adriano Chaves-Filho and the Dr. Sayuri Miyamoto team. To profile oxylipins in amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative dise
6
Neurodegenerative disease research is pleased to announce the progress of developing TVALA for the treatment of neuroinflammation in ALS. You can read about the trial and follow our progress .
23
Indiana University researcher Chandler Walker, Ph.D., developed a stem cell-based secretome therapy that influences both the central and peripheral components of Amyotrophic Lateral Sclerosis (ALS) pa
27
bottom of page